Table 1.
Plasmid Combination | Addgene Cat. No. | Genetic Alteration | Name | Median Survival (DPI) | Reference |
---|---|---|---|---|---|
pT2/SB100x-Luc | 20207 | Luciferase expression | NP | 83–95 | (Calinescu et al., 2015, Koschmann et al., 2016, Núñez et al., 2019, Comba et al., 2020) |
pT/CAGGS-NRASV12 | 20205 | NRASG12V overexpression | |||
pT2/shP53 | 124261 | p53 knock down | |||
pT2/SB100x-Luc | 20207 | Luciferase expression | NPA | 69–80 | (Koschmann et al., 2016, Núñez et al., 2019, Comba et al., 2020) |
pT/CAGGS-NRASV12 | 20205 | NRASG12V overexpression | |||
pT2/shP53 | 124261 | p53 knock down | |||
pT2/shAtrx-GFP4 | 124259 | Atrx knock down | |||
pT2/SB100x-Luc | 20207 | Luciferase expression | NPAI | 163 | (Núñez et al., 2019) |
pT/CAGGS-NRASV12 | 20205 | NRASG12V overexpression | |||
pT2/shP53 | 124261 | p53 knock down | |||
pT2/shAtrx-GFP4 | 124259 | Atrx knock down | |||
pKT-IDH1(R132H)-Katushka | 124257 | IDH1R132H overexpression | |||
pT2/SB100x-Luc | 20207 | Luciferase expression | NPAH | 162 | (Garcia-Fabiani et al., 2020) |
pT/CAGGS-NRASV12 | 20205 | NRASG12V overexpression | |||
pT2/shP53 | 124261 | p53 knock down | |||
pT2/shAtrx-GFP4 | 124259 | Atrx knock down | |||
pKT-H3.3(G34R)-Katushka | - | H3.3G34R overexpression | |||
pT2/SB100x-Luc | 20207 | Luciferase expression | NPAF | 142 | (Comba et al., 2020) |
pT/CAGGS-NRASV12 | 20205 | NRASG12V overexpression | |||
pT2/shP53 | 124261 | p53 knock down | |||
pT2/shAtrx-GFP4 | 124259 | Atrx knock down | |||
pT2-shFYN-GFP4 | - | Fyn knock down | |||
pT2/SB100x-Luc | 20207 | Luciferase expression | NPF | 131 | (Comba et al., 2020) |
pT/CAGGS-NRASV12 | 20205 | NRASG12V overexpression | |||
pT2/shP53 | 124261 | p53 knock down | |||
pT2-shFYN-GFP4 | - | Fyn knock down | |||
pT2/SB100x-Luc | 20207 | Luciferase expression | NPD | 63–69 | (Wiesner et al., 2009, Calinescu et al., 2015, Comba et al., 2020) |
pT/CAGGS-NRASV12 | 20205 | NRASG12V overexpression | |||
pT2-shp53-PDGFβ-GFP4 | - |
p53 knock down PDGFβ overexpression |
|||
pT2/SB100x-Luc | 20207 | Luciferase expression | NPDF | 108 | (Comba et al., 2020) |
pT/CAGGS-NRASV12 | 20205 | NRASG12V overexpression | |||
pT2-shp53-PDGFβ-GFP4 | - |
p53 knock down PDGFβ overexpression |
|||
pT2-shFYN-GFP4 | - | Fyn knock down | |||
pT2/SB100x-Luc | 20207 | Luciferase expression | NL | 30 | (Wiesner et al., 2009, Calinescu et al., 2015) |
pT/CMVSV40-LgT | 20204 | SV40-LgT overexpression | |||
pT/CAGGS-NRASV12 | 20205 | NRASG12V overexpression |
As described in the text, one-day-old mouse pups are injected with a plasmid combination to introduce different genetic alterations into the sub-ventricular zone brain cells. The specific genetic background generated in these cells will define the aggressiveness of the tumor developed and the median survival of tumor bearing mice, measured as days post injection (DPI).